A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Trial Profile

A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Pelareorep (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 26 Jul 2017 According to an Oncolytics Biotech media release, data from this study have been selected for poster presentation (display) at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 10 Jun 2017 Biomarkers information updated
    • 22 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top